PMC:7601109 / 5001-5172 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T28","span":{"begin":45,"end":53},"obj":"Disease"}],"attributes":[{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" and leads to poor outcomes in patients with COVID-19 [18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T82771","span":{"begin":55,"end":57},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T7480","span":{"begin":60,"end":61},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T18967","span":{"begin":111,"end":117},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":" and leads to poor outcomes in patients with COVID-19 [18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"110","span":{"begin":31,"end":39},"obj":"Species"},{"id":"112","span":{"begin":152,"end":162},"obj":"Chemical"},{"id":"113","span":{"begin":164,"end":170},"obj":"Chemical"},{"id":"121","span":{"begin":45,"end":53},"obj":"Disease"}],"attributes":[{"id":"A110","pred":"tao:has_database_id","subj":"110","obj":"Tax:9606"},{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"MESH:C000596367"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"MESH:C000596367"},{"id":"A121","pred":"tao:has_database_id","subj":"121","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" and leads to poor outcomes in patients with COVID-19 [18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338)"}